Pharma Marketing Blog: The Year 2013 in Images
Upcoming SlideShare
Loading in...5
×
 

Pharma Marketing Blog: The Year 2013 in Images

on

  • 19,919 views

These are my favorite images that appeared in Pharma Marketing Blog posts made in 2013.

These are my favorite images that appeared in Pharma Marketing Blog posts made in 2013.

Statistics

Views

Total Views
19,919
Views on SlideShare
4,075
Embed Views
15,844

Actions

Likes
3
Downloads
20
Comments
0

64 Embeds 15,844

http://pharmamkting.blogspot.com 14881
http://pharmamkting.blogspot.in 134
http://pharmamkting.blogspot.co.uk 99
http://pharmamkting.blogspot.com.br 71
http://pharmacoserias.blogspot.com.es 63
http://feeds.feedburner.com 40
http://pharmamkting.blogspot.jp 38
http://pharmamkting.blogspot.de 38
http://pharmamkting.blogspot.fr 36
http://pharmamkting.blogspot.com.es 35
http://pharmamkting.blogspot.ca 34
http://feedly.com 34
http://pharmacoserias.blogspot.com 29
https://twitter.com 25
http://pharmamkting.blogspot.ch 25
http://pharmamkting.blogspot.mx 23
http://www.forums.pharma-mkting.com 22
http://pharmamkting.blogspot.kr 17
http://www.newsblur.com 16
http://pharmamkting.blogspot.it 16
http://pharmamkting.blogspot.nl 14
http://pharmamkting.blogspot.ru 13
http://pharmamkting.blogspot.hu 10
http://pharmamkting.blogspot.sg 9
http://pharmamkting.blogspot.com.au 8
https://pharmacoserias.blogspot.com 8
http://www.pharmamkting.blogspot.co.uk 7
http://pharmamkting.blogspot.co.at 7
http://pharmamkting.blogspot.be 7
http://news.google.com 6
http://pharmamkting.blogspot.ie 5
http://pharmamkting.blogspot.se 5
http://www.feedspot.com 5
http://pharmamkting.blogspot.tw 4
https://www.blogger.com 4
http://pharmacoserias.blogspot.com.ar 4
http://pharmamkting.blogspot.hk 4
http://pharmamkting.blogspot.pt 4
https://www.google.com 3
http://digg.com 3
http://pharmamkting.blogspot.gr 3
https://www.facebook.com 2
http://pharmamkting.blogspot.ro 2
http://newsblur.com 2
http://pharmamkting.blogspot.ae 2
http://pharmacoserias.blogspot.se 2
http://pharmamkting.blogspot.co.nz 2
http://forums.pharma-mkting.com 2
http://pharmacoserias.blogspot.mx 2
http://pharmamkting.blogspot.sk 2
More...

Accessibility

Upload Details

Uploaded via as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment
  • My take on the ascendancy of biologics in terms of dollar sales: Many of these drugs are so damn expensive that relatively few patients are required to reach the annual sales numbers heretofore reached by small molecules such as Lipitor and Plavix.However, even some “small molecules” may command high prices in the future. Pfizer's Xalkori (crizotinib), for example, is a small molecule drug that was recently approved to treat a rare form of lung cancer. Pfizer plans to charge $115,200 a year per patient for treatment with Xalkori. At that rate, Pfizer needs only about 9,000 patients worldwide to generate $1 billion in annual sales of Xalkori. In comparison, 1,671,000 Lipitor patients are required to generate the same sales figure.
  • Ian Wilson’s group has been studying the rare antibodies produced in some people that bind to regions of the virus coat protein that do not change as quickly as the typical targets. “The hope is that these antibodies will be able to recognize many different strains of the virus,” reports MIT Technology Review.Back in the 80s, when I built this model, computer graphics were not good enough to help scientists like Wilson visualize the detailed structure of proteins. Here’s how Dr. Wilson describes my tiny contribution to his research:“We decided we would have a go at building a trimer so we co-opted John Mack from New York who was a model builder. He came up to Harvard [I built a model there first] and we constructed a dimer as one unit. This was a three-dimensional plastic model, 1 angstrom per cm. We could actually look at this thing to see what it really looked like and we could obviously trace it out. There were some limited computer-graphics programs that you could use to trace out the molecule, but it was really hard to get a feel for what it was all like without seeing everything at once. So that (three-dimensional) model turned out to be extraordinarily useful for trying to understand the structure. The third monomer was also built and we thought we would be able to assemble and disassemble the trimer, but they were so intertwined that it was impossible.”It's great to be a small part of the history of virology, but it would be even better if that history eventually includes the successful development of a universal vaccine for the flu.
  • The sculpture seems like it is capturing minimal attention from Victoria Station visitors of which there are 1.5 million per week! The photo shows one person eying the sculpture wondering what it is.But it's not the inhaler itself that contributes to GSK's global carbon footprints. 95% of the footprint produced by these inhalers is a result of the propellant it releases into the atmosphere. Even Claes Oldenburg would be challenged to sculpt propellant!P.S. Why green? I think the actual inhalers come only in beige like old-style personal PCs. Claes would not approve!
  • MrVasella “has agreed to continue to make available his knowhow to Novartis and to refrain from activities that compete with any business of Novartis for a multiyear period.” I’m not sure what the shelf-life of foods preserved in aspic is, but Vasella’s shelf-life deal runs for 6 years.Update: The shelf-life turned out to be less than 1 day! Novartis Board of Directors and Dr. Daniel Vasella agreed to cancel the non-compete agreement and all related compensation. The decision, Novartis said, was taken “to address concerns of stakeholders.” But I think the image of Vasella preserved in Aspic is what did the deal in. Talk about an image worth a thousand words... the above image may have been worth $78 million!
  • Taking iPads away from sales reps to run desktop programs like Excel is so old school! It's an example of how legacy systems are putting pharma on the wrong side of the digital divide.What do sales reps use Excel for? The major use seems to be travel and expense reporting. Why isn't there a mobile app for that? Pharma IT people should be able to create these or buy them from vendors pretty easily. Are they “Nazis” or just lazy or too cheap? Maybe they’re just anti-iPad.Another “hurdle” to iPad adoption I heard was that many Web pages that sales reps need to access on mobile devices like smartphones and iPads do not display very well on these devices. Duh! I’ve already explained how pharma could greatly benefit by optimizing their web sites for mobile.When I pointed out these and few other “technical” tips to the people at the table, you would have thought I was a technology genius! One woman asked me if I had any other good ideas. That’s when I handed out my infamous @Pharmaguy card with the QR codes. That, of course, lead to another discussion—about QR codes—What are they? How do I read them?, etc.Some day this stuff will be as simple as pie for pharma marketers. Right now, however, I am a big fish swimming in a small pond.
  • In testimony before the U.S. House of Representatives Energy and Commerce Committee Subcommittee on Communications & Technology, several expert witnesses alluded to “garage entrepreneurs” as the driving force behind the “tra-jectory of innovation” in the development of mobile health apps. They worry that such “small” enterprises do not have the money or knowledge to deal with FDA regulation, especially when it is uncertain which mobile health apps the FDA will or will not deem to be medical devices subject to regulation.It's a well-known fact that pharma companies and their agencies typical outsource the development of their digital applications and usually the supplier is a lone developer working at home.So, is the typical developer of mobile health apps sponsored by pharma a lone, young man 29 years or less old?
  • What is the cause of the downward spiral of DTC ad spending? Practically every expert points to the “patent cliff,” over which much of the industry has already fallen. There must be other factors. I have presented some data that suggests a role for the rise in biologics, many of which are too complicated and have too many serious side effects to be marketed via DTC. It's not as if a consumer can “ask her doctor” for a specific cancer treatment regimen, for example. Although I do see DTC ads for biologics, I believe most biologics marketing dollars will be spent on physician and payer sales and marketing. So, even when biologics are advertised on TV, the ROI is not as high as for drugs with a much bigger potential patient pool. That would mean fewer TV and print ads.
  • The tubs image, of course, recalls DTC ads for Cialis. According to Nielsen data, which you can find in the MM&M report, Cialis ranked #2 in DTC ad spending in 2012, just behind Cymbalta. That's an increase in 13% over the 2011 spend (those tubs aren't drained just yet!). The Viagra ad spend, on the other hand, decreased 15%. Oh well, one man's Viagra is another man's Cialis!
  • A Wall Street Journal article reported that Eli Lilly will lay off 30% of its U.S. salesforce. Why? Generics, of course, was mentioned first. But if you read on, you will find this tidbit:Also, the influence of sales representatives has shrunk, as many physicians no longer have the time to take the calls and some doctors refuse to see pharmaceutical representatives out of concern about improper promotions. Growing numbers of doctors prefer digital marketing. Lilly's U.S. sales force “will move to a smaller structure that is more directly aligned with our business realities—along with the realities our customers face, and the way they want to interact with us,” a spokesman said.
  • When the pharma social media hopefuls et al saw no looming guidance they sternly said, “Save your hopeful song for when there is really some guidance coming along! Don't cry ‘soon’ when there is NO soon!”
  • DOJ claims that Novartis violated the Anti-Kickback Statute by paying doctors to speak about certain drugs, including its hypertension drugs Lotrel and Valturna and its diabetes drug Starlix, at events that were often little or nothing more than social occasions for the doctors. The payments and lavish dinners given to the doctors were, in reality, kickbacks to the speakers and attendees to induce them to write prescriptions for Novartis drugs, says DOJ.Many speaker programs were held in circumstances in which it would have been “virtually impossible for any presentation to be made, such as on fishing trips off the Florida coast,” the suit claims.Other Novartis events were held at Hooters restaurants.Stories like this are why I love my job! It’s a great excuse for me to Google images of Hooters' girls—even with Mrs. Pharmaguy peering over my shoulder—to come up with the above fictitious interview of a Hooters Waitress of the Month who was present on several occasions when Novartis reps and their clients held “educational” events at the Hooters restaurant where she worked.Posted April 27, 2013http://bit.ly/PMBalbum042713
  • I would guess that no matter how the question about inappropriate prescribing was phrased, most respondents were thinking of the effect of DTC advertising on OTHER doctors’ prescribing, not THEIRS. It's similar to how doctors feel about free lunches—they believe OTHER doctors are influenced by free lunch.When the FDA announced it was moving ahead with yet another study of direct-to-consumer (DTC) advertising, I said:“Very few healthcare professionals are going to admit that advertising ADVERSELY affects their clinical decisions. Most would say it has no effect at all and many would say it has a positive effect; don't forget all the money many physicians have received from the drug industry, which they also say does not influence their prescribing habits.”
  • This chart is about “measured media” spending focused on healthcare professionals (HCPs). “Print Media” refers to ads in medical journals, “Reprints” refers to reprints of medical journal articles that sales reps hand out to physicians, and “Digital Media” refers to online ads placed on sites frequented by physicians (e.g., WebMD). “All Other” includes Convention Media (ads at medical conventions), In-Office Media (I'm not sure what's included in this; whatever it is, it's less than 1% of the total spend), Point of Care Media (patient record forms, prescription pads and the like), and Direct Mail. This analysis does NOT including detailing spend, which is the biggest promo-tional spend by pharma.
  • Bayer HealthCare Grants4Apps™ invites health app developers to submit their innovative app ideas for novel software that contributes to improving health outcomes or pharmaceutical processes. Bayer HealthCare considers an “App” any software solution running on any platform. Selected projects are supported with an amount of either 5.000€ or 10.000€. Dr. Jesus del Valle (@yeysus), project leader of the Bayer HealthCare Grants4Apps™ (@grants4apps) program, invited me to speak at a “Bayer Meets Startups!” event, Tuesday, 11 June, 2013, in Berlin. The title of the event was “Bayer Pharma Meets Pharmaguy Meets [Healthcare App] Startups.”
  • The Roche Digital Academy concluded with Graduation day on July 1, 2013. This training program, developed by the Digital Team Roche Italy, in collaboration with the School of Communication and Iulm in Milan, was attended by 80 professionals working in the company. Graduates received a Master in Digital Marketing, specifically designed for the pharmaceutical industry.(Left to right: AlessiaFerrario, eLearning Specialist; Gaetano Vancheri, eMarketing Specialist; DavideBottalico, MD, Marketing Manager Digital Area; Pharmaguy; Denis Dina, Digital Strategic Planner; and StefaniaNicastro, eMarketing Specialist)
  • The pharmaceutical industry has often been criticized for being behind the “digital curve,” meaning that it lacks the expertise to fully take advantage of the Internet and other technology to improve marketing and communications. Although some pharma companies are digital “dunces,” others are digital “geniuses.”Now that pharma is seriously pushing the digital agenda WITHIN their organizations, technology innovators should get on the bandwagon and reap the benefits. I know I am, even though I am not a “technology” person per se. My technology is the critical human brain attached to a computer with Internet access AND the advantage of looking in from the outside.
  • According to RocketNews24, “while many applauded the creativeness of these fans, many net users wrote it off as ‘gay’ or ‘just for fujoshi’.” According to wikipedia, fujoshi is a self-mockingly pejorative Japanese term for female fans of novels that feature romantic relationships between men.The Viagra fans are from a few years back, and some commenters say they received them at various events. “It’s a testament to its effectiveness how even after so long someone can still rack up over 12,000 retweets from posting it.”The fans may be an effective marketing ploy, but are not very effective in keeping you cool. Perhaps, like Viagra, only 25% of men find them effective?
  • The authors identify six “principles of influence” that are “key to the industry’s routine marketing strategies, which rely on the illusion that the industry is a generous avuncular partner to physicians”:reciprocation,commitment,social proof,liking,authority, andscarcityBut resistance is NOT futile, say the authors. “In order to resist industry influence, physicians must accept that they are vulnerable to subconscious bias and have both the motivation and means to resist industry influence.”Sounds like physicians need a 12-Step program to wean themselves off psychological dependence on pharma marketing!
  • On the day I arrived—without my luggage!—I was interviewed by Teresa BauPuig (@tbau_uoc), a freelance journalist, communication and social media consultant from Barcelona. The interview is written in the Catalan language, but you can find the English translation in this blog post.
  • Back in 2011, when Senak first began tracking pharma on Google+, I predicted that there would be a rush to Google+ by pharma marketers in order to get in on the ground floor of another social media eyeball fest! At the time, I heard that some companies were reserving Google+ account names without having any specific plans for how they will use it. Senak's accounting confirms my suspicions.
  • Upon completion of the course, participants are told they will be able to:Identify the role that FDA, OPDP and HCPs play in regulating prescription drug promotion and advertising Describe the most common regulatory issues raised by prescription drug promotion Recognize false or misleading prescription drug promotionIn my case, the course succeeded in achieving those learning objectives.One other objective not mentioned is that this course obviously promotes the BadAd program and emphasizes how to submit a complaint to the program several times throughout the course. Unfortunately, there are only two options for submitting a complaint: (1) by email or (2) by phone. The course even includes a video of how to submit a complaint via email!I guess the FDA hasn't heard that practically every physician uses an iPhone and/or iPad. Why not have a convenient mobile app for reporting complaints about ads? The FDA obviously spent a ton of money on the course, but skimped on the most important part of its program -- making it easy for docs to submit complaints!
  • Johnson and Johnson (J&J) and its subsidiary companies Janssen Pharma-ceuticalsand Scios Inc. have agreed to pay more than $2.2 billion in fines for inappropriately, and in some cases illegally, promoting prescription drugs. In addition, according to the Wall Street Journal, J&J “agreed to pay about $2.5 billion to resolve thousands of lawsuits filed by patients who allege they were hurt by some of the health-product maker's artificial hips... One person familiar with the settlement talks said J&J will pay off liens costing around $60,000 to $75,000 for each patient; the liens were taken by government health plans like Medicare and private insurers while covering the medical costs of the patients, and could amount to an additional $600 million, the person said.”
  • Perhaps drug advertisers never use the word “fatal,” but I have seen many TV drug ads that mention death as a possible side effect. In 2007, for example, Pfizer ran a 250-second TV ad for Celebrex that mentioned “death” due to side effects at least two times.At the time, Bruce Grant—another pharma marketing expert —said “I can’t even begin to imagine how much Pfizer is spending on this campaign at 250 seconds of airtime a pop. And by returning to the airwaves, they’ve just plastered a big ‘Kick Me’ sign on their back for Sidney Wolfe, Senator Grassley, Rep. Waxman, et al. Whoever sold this idea to Pfizer management must be one heck of a salesperson.”A poll of my readers indicated that not every viewer of the Celebrex ad got the message of death, although most did get the positive messages. So, mentioning death is not as fatal as some experts may think.
  • FDA is concerned about the public health consequences of inaccurate results from the PGS device.The author of the letter—Alberto Gutierrez, Director of FDA's Office of In vitro Diagnostics and Radiological Health—seems pretty miffed at 23andme. You might even say he's "spitting mad" as indicated by the tome of the letter. “even after ... many interactions with 23andMe,” said Gutierrez, “we still do not have any assurance that the firm has analytically or clinically validated the PGS for its intended uses.”Aside from 23andMe's lack of response to FDA, Anne Wojcicki, CEO of 23andMe, may have pissed off the FDA with her combative stance viz-a-viz fighting the regulators for the sake of preserving the “customer experience.”“What is the best customer experience?,” asked a commenter, “Fast but unreliable results?”
  • If the drug industry stopped illegally promoting drugs for unapproved uses and spent as much time and effort on improving medication adherence as it spends on these court cases and waste disposal educational programs, the problem of unused drugs might be solved without the need for “SMARxT” disposal plans.To the extent that the industry is opposing these municipal disposal plans for economic reasons, it may wish to reconsider this stance that just doesn't look good from a PR perspective, especially when the 11 largest pharmaceutical companies reported $85 billion in profits last year, according to publicly available reports. If the industry took responsibility for what happens to their products after the sale is made -- as recommended by Seattle City council member and county Board of Health vice chair Richard Conlin -- the industry would win very big in the public reputation department.
  • The Roche Digital Team presented at the 2013 IAB Forum and mentioned receiving the 4th Annual Pharmaguy Social Media Pioneer Award.
  • If you think this kind of thing is not possible, consider this case. NBC News described a liver transplant team’s quandary over its discovery of a Twitter photograph of a patient drinking alcohol — an obvious no-no that could disqualify him from the life-saving surgery.With social media monitoring/listening tools and minimal personal information, it may be possible to actively monitor individual patients on social media.But if pharma did this, it would go too far.Three basic principles should be part of any social media code of ethics: Notification to patients; The right of patients to “rebut, explain or challenge” the information; and A ban on what he calls “systematic snooping or surveillance.” “If social media info is used in patient care,” says Art Caplan, director of the division of medical ethics at New York University’s Langone Medical Center, “my view is that it ought to be disclosed to [the] patient.” Now, that’s a patient-centric approach!

Pharma Marketing Blog: The Year 2013 in Images Pharma Marketing Blog: The Year 2013 in Images Presentation Transcript

  • THE YEAR 2013 IN IMAGES T H E S E A R E M Y FA V O R I T E I M A G E S T H AT A P P E A R E D I N PHARMA MARKETING BLOG POSTS MADE IN 2013
  • LIPITOR & PLAVIX: THE LAST OF THE SMALL MOLECULE BEST SELLERS? The products in the Forbes list of “Best Selling Drugs of All Time” that are best positioned to record an increase in peak annual sales over the next five years are biologics. Humira, Enbrel, Rituxan, Herceptin and Lantus being the chief candidates. Posted January 28, 2013. http://bit.ly/PMBalbum012813 Pharma Marketing Blog 2013: The Year in Images  2013. Pharma Marketing Network. All rights reserved.
  • ELUSIVE UNIVERSAL FLU VACCINE I once made a living building molecular models of complex proteins for life science researchers. One such model was of the influenza flu coat protein, which I built for Dr. Ian Wilson, who is now Chairman of the Department of Integrative Structural and Computational Biology at The Skaggs Institute for Chemical Biology, which is part of the Scripps Research Institute. The model is currently on display in the lobby of the Institute. The model looks as if it were built yesterday! Kudos to Scripps for the excellent maintenance. Posted January 29, 2013. http://bit.ly/PMBalbum012913 Pharma Marketing Blog 2013: The Year in Images  2013. Pharma Marketing Network. All rights reserved.
  • GSK: THE CLAES OLDENBURG OF PHARMA GSK launched a recycling program that includes an “Oldenburgesque” large-scale sculpture of a mundane object—a metered dose inhaler! Here it is in London’s Victoria Station. Posted February 11, 2013. http://bit.ly/PMBalbum021113 Pharma Marketing Blog 2013: The Year in Images  2013. Pharma Marketing Network. All rights reserved.
  • AN ANTI-DTC CROSSWORD PUZZLE The theme of this Newsday crossword puzzle was an anti direct-toconsumer (DTC) TV ad quip: “ASK YOUR DOCTOR IF TAKING MEDICAL ADVICE FROM A TV AD IS RIGHT FOR YOU” This is a take-off of the call to action of every DTC TV ad; i.e., “Ask Your Doctor if [INSERT BRAND NAME DRUG HERE] is right for you.” Posted February 15, 2013. http://bit.ly/PMBalbum021513A Pharma Marketing Blog 2013: The Year in Images  2013. Pharma Marketing Network. All rights reserved.
  • NOVARTIS PRESERVES VASELLA IN ASPIC Novartis reached a deal to retain former CEO Vasella as a paid consultant restrained from working for competitors for a number of years. “After 17 years in charge,” said the Financial Times, “there is little more he can offer Novartis. His wealth of experience would be better employed advising start-ups and on new drug development. Instead, it will be preserved in aspic inside Novartis.” I thought the “preserved in aspic” comment deserved a visual rendering. Posted February 18, 2013. http://bit.ly/PMBalbum021813 Pharma Marketing Blog 2013: The Year in Images  2013. Pharma Marketing Network. All rights reserved.
  • LAZY IT “NAZIS” THWART IPAD USE BY SALES REPS During a roundtable discussion at a Sample Management and Mobile Sales conference, I heard from some pharma people about the “limitations” of iPad use by sales reps. One person mentioned that her IT people took away all the iPads from reps and replaced them with MS Surface Tablets so that reps can use MS Excel and Word desktop appli-cations without switching to a laptop. Someone at the table called this “The Excel Spreadsheet Hurdle.” Posted March 20, 2013. http://bit.ly/PMBalbum032013 Pharma Marketing Blog 2013: The Year in Images  2013. Pharma Marketing Network. All rights reserved.
  • IS THIS THE TYPICAL MOBILE HEALTH APP DEVELOPER HIRED BY PHARMA? The availability of so many mobile health apps and the low economic and technical barriers to entry in this market begs the question: Who is the typical mobile Health App Developer? The closest I could come to the answer to that question is this graphic in an article published in the Wall Street Journal. Posted March 28, 2013. http://bit.ly/PMBalbum032813 Pharma Marketing Blog 2013: The Year in Images  2013. Pharma Marketing Network. All rights reserved.
  • DIGITAL AD SPENDING DOWN ONE-THIRD! Nielsen data indicate that the overall decline in DTC spending in 2012 was 11-12% compared to 2011. Meanwhile, TV ad spending decreased 10% whereas Internet display ad spending (excluding search) decreased 33%! Internet measured media spending is only 2% of the total. This is a number that hasn't changed much since 2000 when I started tracking it. Posted April 2, 2013. http://bit.ly/PMBalbum040213 Pharma Marketing Blog 2013: The Year in Images  2013. Pharma Marketing Network. All rights reserved.
  • DTC DOWN THE DRAIN “Direct-to-consumer advertising, as we’ve known it, at least, is not the be-all and end-all of marketing prescription drugs to patients anymore,” said Matthew Arnold in an MM&M report with the provocative title “DTC Drain.” Yes, and the spending trend shows it. DTC ad spending decreased 12% in 2012 compared to 2011. Posted April 4, 2013. http://bit.ly/PMBalbum040413 Pharma Marketing Blog 2013: The Year in Images  2013. Pharma Marketing Network. All rights reserved.
  • PHARMA SALES JOBS TAKE A(NOTHER) TUMBLE! Jack vs. Jill, Two Different Kinds of Pharma Sales Reps Jack, the traditional pharma sales rep, drove his Ford Taurus all around town, To detail and distribute free samples to his physician clients. Jack banged his head against a doc’s door and broke his crown, Because physicians would not let him in to see and feed them. Meanwhile, Jill the virtual pharma sales rep, opened her iPad, To Skype & email her physician clients and offer them free sample coupons. She “visited” many docs this way, made a bundle, and was glad, Because busy physicians prefer to get drug info & samples "virtually.” Posted April 12, 2013. http://bit.ly/PMBalbum041213 Pharma Marketing Blog 2013: The Year in Images  2013. Pharma Marketing Network. All rights reserved.
  • THE FDA DIRECTOR MAN WHO CRIED “SOON!” There once was an FDA-OPDP Director man who was besieged whenever he spoke to conference attendees and the press. “When will you publish the social media guidance you promised?”, he was asked. To save himself from further shame he took a great breath and sang out, "Soon! Soon! The social media guidance is coming … soon!” The pharma social media hopefuls & pundits & consultants came running up the Hill to visit the Director man to drive all doubt away. But when they arrived at the Hill, they found no guidance. The Director man laughed at the sight of their angry faces. Posted April 16, 2013. http://bit.ly/PMBalbum041613 Pharma Marketing Blog 2013: The Year in Images  2013. Pharma Marketing Network. All rights reserved.
  • NOVARTIS WINES—ER, BEERS—AND DINES DOCS AT HOOTERS! Pharma Marketing Blog 2013: The Year in Images  2013. Pharma Marketing Network. All rights reserved.
  • MOST PHYSICIANS AGREE THAT DTC ADVERTISING LEADS TO INAPPROPRIATE PRESCRIBING A snap poll of 104 physicians by CMI/Compas revealed that nearly two-thirds of both primary care and specialty physicians agree (20% strongly; 45% somewhat) that DTC pharmaceutical advertising leads to inappropriate prescribing. Posted May 2, 2013. http://bit.ly/PMBalbum050213 Pharma Marketing Blog 2013: The Year in Images  2013. Pharma Marketing Network. All rights reserved.
  • WAS 2013 THE YEAR OF “DIGITAL PHARMA” (FOR HCP PROMOTION)? Forecasters predicted that Healthcare Professional (HCP) MEASURED MEDIA digital spending by pharma will equal that of print in 2013. Digital promotion is only 5.2% of the $17 billion total spent on HCP promotion (including detailing). This means that the U.S. pharma industry, which spends nearly $1 billion on professional digital promotion, has a long way to go before it reaches “digital maturity” on a par with other industries. I estimate that “par” to be 20%. Posted May 21, 2013. http://bit.ly/PMBalbum052113 Pharma Marketing Blog 2013: The Year in Images  2013. Pharma Marketing Network. All rights reserved.
  • PHARMAGUY EU TOUR 2013: THE INFOGRAPHIC This infographic was created as I was making my “Overcoming Pharma's Social Media & Mobile Challenges” presentation at Bayer Healthcare’ HQ in Berlin as part of the HealthCare Grants4Apps™ program. Posted June 19, 2013. http://bit.ly/PMBalbum061813 Pharma Marketing Blog 2013: The Year in Images  2013. Pharma Marketing Network. All rights reserved.
  • GRADUATION DAY AT THE ROCHE DIGITAL ACADEMY I was a guest “lecturer” at the Academy in June and received the Academy’s 2013 Award for “Performance in Excellence in Social Media Regulatory Management.” Posted July 3, 2013. http://bit.ly/PMBalbum070313 Pharma Marketing Blog 2013: The Year in Images  2013. Pharma Marketing Network. All rights reserved.
  • THE “PHARMA DIGITAL HYPE CYCLE” Lately, several major pharma companies have initiated programs to identify, reward, and work with innovative technology companies, and to increase the digital “smarts” of their employees via structured educational activities. Is pharma on the path to benefiting from all this technology being developed by innovative companies? I modified the “Gartner Hype Cycle” graph to illustrate where I believe pharma is today. My version is called the “Pharma Digital Hype Cycle.” Posted July 19, 2013. http://bit.ly/PMBalbum072913 Pharma Marketing Blog 2013: The Year in Images  2013. Pharma Marketing Network. All rights reserved.
  • FANS & BANANAS: VIAGRA ADS IN JAPAN As reported by RocketNews24, hand-held fans like these—emblazoned with commercial messages and logos—are popular in Japan when it gets hot. Personally, I'd rather die of heat exhaustion than use these fans in public! (although I'd love to get my hands on one :-). Posted July 29, 2013. http://bit.ly/PMBalbum072913 Pharma Marketing Blog 2013: The Year in Images  2013. Pharma Marketing Network. All rights reserved.
  • PHYSICIANS ARE POWERLESS PAWNS OF PHARMA PSYCHOLOGY According to Harvard and Georgetown University ethicists and academics, “pharmaceutical and medical device companies apply social psychology to influence physicians’ prescribing behavior and decision-making.” “Physicians fail to recognize their vulnerability to commercial influences due to selfserving bias, rationalization, and cognitive dissonance,” claim the authors. Moreover, the authors claim that “professionalism offers little protection; even the most con-scious and genuine commitment to ethical behavior cannot eliminate unintentional, subconscious bias.” Posted August 17, 2013. http://bit.ly/PMBalbum081713 Pharma Marketing Blog 2013: The Year in Images  2013. Pharma Marketing Network. All rights reserved.
  • BARCELONA, CATALONIA, AND GLOBAL PHARMAGUY Many Catalonians want independence from Spain. While attending the 3rd Annual Pharma eMarketing Congress in Barcelona, Spain, I joined the September 11 “Human Chain” demonstration in the Plaça d'Espanya just prior to 17:14, which symbolizes the year 1714 when King Philip V abolished the Generalitat after the War of the Spanish Succession. Does that mean I support the independence of Catalonia? I'm not sure. I was there because it was an event not to be missed and why not take part rather than just observe? It's what a true proponent of social media would do and since there was no “counter” demonstrators, I joined the line. Posted September 17, 2013. http://bit.ly/PMBalbum091713 Pharma Marketing Blog 2013: The Year in Images  2013. Pharma Marketing Network. All rights reserved.
  • JUST AS I SUSPECTED: PHARMA COMPANIES SET UP GOOGLE+ GHOST TOWNS Eye On FDA's Mark Senak is keeping tabs on pharma’s social media assets. With regard to Google+, Senak notes that there are 79 Google+ pages in his database that are sponsored by pharma companies. Of these, 31 have no followers at all and 23 are inactive. Posted October 29, 2013. http://bit.ly/pgdaily102913-3 Pharma Marketing Blog 2013: The Year in Images  2013. Pharma Marketing Network. All rights reserved.
  • FDA’S BADAD CE PROGRAM I completed FDA’s BadAd online course for healthcare professionals who can earn Continuing Education (CE) credits while learning how to identify potentially untruthful or misleading drug ads and promotional materials. The course is offered on Medscape. Although I don't get any CE credits—I only pretend to be a doctor on Medscape—I did get a nice Certificate of Completion at the end of the course. Posted October 29, 2013. http://bit.ly/PMBalbum102913 Pharma Marketing Blog 2013: The Year in Images  2013. Pharma Marketing Network. All rights reserved.
  • J&J JOINS PHARMAGUY’S CRIMINAL & CIVIL SETTLEMENT PLANETARY SYSTEM Johnson and Johnson agreed to pay $5.3 Billion in fines and settlement fees, which may represent as much as one-third of J&J's annual profits! The Pharmaguy “Pharma Criminal & Civil Settlement Planetary System” poster was updated to illustrate the seven highest multi-million/billion dollar settlements that drug companies have agreed to pay federal and state authorities for inappropriately, and in some cases illegally, promoting prescription drugs. Posted November 13, 2013. http://bit.ly/pgdaily111313-2 Pharma Marketing Blog 2013: The Year in Images  2013. Pharma Marketing Network. All rights reserved.
  • PHARMA TV ADS SHOULDN’T DROP THE “F BOMB,” SAYS EXPERT. I DISAGREE. Fearing that mentioning a list of “really bad potential side effects” in TV DTC ads turns consumers off, blogger Richard Meyer offered this advice: “If your product has fair balance that includes the word ‘fatal’ think about the channel you’re using.” Using urban slang, Meyer's advice to pharma marketers might be summed up as: Do not use the “F (fatal) Bomb” in TV ads. Posted November 22, 2013. http://bit.ly/pgdaily112213-2 Pharma Marketing Blog 2013: The Year in Images  2013. Pharma Marketing Network. All rights reserved.
  • FDA AXES MARKETING OF 23ANDME’S “SPIT FOR CANCER” KIT The FDA sent a WARNING letter to the CEO of 23andMe saying the company illegally marketed its 23andMe Saliva Collection Kit and Personal Genome Service. Genentech teamed up with 23andMe—a personal genetics firm—to collect spit from volunteers to find out why people respond differently to Avastin, which is Genentech's expensive (up to $100,000 per year per patient) drug for the treatment of metastatic colorectal cancer, among others. Posted November 25, 2013. http://bit.ly/pgdaily112613-1 Pharma Marketing Blog 2013: The Year in Images  2013. Pharma Marketing Network. All rights reserved.
  • PHRMA SAYS THROW UNUSED DRUGS IN HOUSEHOLD TRASH The pharmaceutical industry is challenging local governments over ordinances that require drug makers to cover the cost of prescription drug “take back” disposal programs. Through its “SMARxT Disposal Program,” PhRMA is “educating” consumers and urging them to discard unused pills with “normal household trash” and let Waste Management or some other trash disposal company dispose of it in landfills or wherever. Posted December 4, 2013. http://bit.ly/pgdaily120913-1 Pharma Marketing Blog 2013: The Year in Images  2013. Pharma Marketing Network. All rights reserved.
  • MY MAN IN MILAN You have to be a big guy or gal in the pharma social media arena to wear the shirt off my back. Davide Bottalico, MD, Digital Marketing Manager at Roche, Italy, fits the bill as is obvious from this photo taken at the IAB Forum 2013 Milano. Posted December 6, 2013. http://bit.ly/PMBalbum120613 Pharma Marketing Blog 2013: The Year in Images  2013. Pharma Marketing Network. All rights reserved.
  • BEING TOO “PATIENT-CENTRIC”: SPYING ON PATIENTS ON SOCIAL MEDIA “Patient-Centricity” seems to be an overused buzzword among pharma marketers these days. Using “publicly available information,” it is possible to find and track conversations of individual patients on Twitter and Facebook using Big Data analytics. Now that would be patientcentric—maybe TOO patientcentric. Posted December 11, 2013. http://bit.ly/pgdaily121213-1 Pharma Marketing Blog 2013: The Year in Images  2013. Pharma Marketing Network. All rights reserved.
  • WISHING YOU A HAPPY NEW YEAR! Pharma Marketing Blog 2013: The Year in Images  2013. Pharma Marketing Network. All rights reserved.